- Home
- CASS vs OCS Comparison
CASS vs OCS Comparison
Compare CASS & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CASS
- OCS
- Stock Information
- Founded
- CASS 1906
- OCS 2003
- Country
- CASS United States
- OCS Switzerland
- Employees
- CASS N/A
- OCS N/A
- Industry
- CASS Business Services
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- CASS Consumer Discretionary
- OCS Health Care
- Exchange
- CASS Nasdaq
- OCS Nasdaq
- Market Cap
- CASS 586.3M
- OCS 689.8M
- IPO Year
- CASS 1996
- OCS N/A
- Fundamental
- Price
- CASS $42.27
- OCS $18.58
- Analyst Decision
- CASS Buy
- OCS Strong Buy
- Analyst Count
- CASS 1
- OCS 4
- Target Price
- CASS $46.00
- OCS $31.50
- AVG Volume (30 Days)
- CASS 58.6K
- OCS 30.4K
- Earning Date
- CASS 04-17-2025
- OCS 05-08-2025
- Dividend Yield
- CASS 2.93%
- OCS N/A
- EPS Growth
- CASS N/A
- OCS N/A
- EPS
- CASS 1.53
- OCS N/A
- Revenue
- CASS $220,944,000.00
- OCS $847,333.00
- Revenue This Year
- CASS N/A
- OCS $49.27
- Revenue Next Year
- CASS $7.19
- OCS $1,920.31
- P/E Ratio
- CASS $28.04
- OCS N/A
- Revenue Growth
- CASS 2.32
- OCS N/A
- 52 Week Low
- CASS $37.99
- OCS $10.79
- 52 Week High
- CASS $47.14
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- CASS 57.46
- OCS 54.68
- Support Level
- CASS $41.04
- OCS $18.01
- Resistance Level
- CASS $42.79
- OCS $19.50
- Average True Range (ATR)
- CASS 0.94
- OCS 0.77
- MACD
- CASS 0.29
- OCS 0.17
- Stochastic Oscillator
- CASS 83.49
- OCS 66.30
About CASS Cass Information Systems Inc
Cass Information Systems Inc is a provider of payment and information processing services to large manufacturing, distribution and retail enterprises across the United States. The company provides transportation invoice rating, payment processing, auditing, accounting, and transportation information. It is also a processor and payer of energy invoices, including electricity, gas, waste, and other facility-related expenses. It operates in two segments: Information Services and Banking Services. The firm generates maximum revenue from the Information Services segment.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.